Robert B. Berryman

Robert B. Berryman

Hematology | Oncology

400 Rosalind Redfern Grover Pkwy
Ste 100
Midland, TX 79701

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

Journal: Leukemia & lymphoma

Published: August 12, 2014

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Journal: Cancer chemotherapy and pharmacology

Published: January 21, 2013

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.

Journal: Bone marrow transplantation

Published: November 27, 2012

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Journal: Blood

Published: April 19, 2012

Showing 1-4 of 4

Last Updated: 09/26/2026